Becton, Dickinson and Co. Quarterly Earnings Sneak Peek
S&P 500 (NYSE:SPY) component Becton, Dickinson and Co. (NYSE:BDX) will unveil its latest earnings on Tuesday, August 2, 2011. Becton, Dickinson & Co offers laboratory equipment, medical supplies, devices and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories and individual consumers.
Becton, Dickinson and Co. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.43 per share, a rise of 10.9% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.42. For the year, analysts are projecting profit of $5.62 per share, a rise of 14.7% from last year.
Past Earnings Performance: The company has beaten estimates the last two quarters and is coming off a quarter where it topped the forecasts by 8 cents, reporting net income of $1.38 per share against a mean estimate of profit of $1.30. In the first quarter, the company exceeded forecasts by 6 cents with net income of $1.35 versus a mean estimate of profit of $1.29.
Wall St. Revenue Expectations: On average, analysts predict $1.99 billion in revenue this quarter, a rise of 5.9% from the year ago quarter. Analysts are forecasting total revenue of $7.78 billion for the year, a rise of 5.6% from last year’s revenue of $7.37 billion.
Analyst Ratings: Analysts seem relatively indifferent about Becton, Dickinson and with 13 of 19 analysts surveyed maintaining a hold rating.
A year-over-year revenue increase in the second quarter snaps a streak of two consecutive quarters of revenue declines. Revenue rose 4.2% in the second quarter and fell 3.9% in the first quarter and 8.7% in the fourth quarter of the last fiscal year.
The company has now been profitable for the last eight quarters, and for the last four, profit has risen year over year by an average of 4.9%. The quarter with the biggest boost was the fourth quarter of the last fiscal year, which saw a 25.1% surge.
Competitors to Watch: Covidien plc (NYSE:COV), Thermo Fisher Scientific Inc. (NYSE:TMO), C.R. Bard, Inc. (NYSE:BCR), Teleflex Incorporated (NYSE:TFX), Retractable Tech., Inc. (AMEX:RVP), Hologic, Inc. (NASDAQ:HOLX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Medical Action Industries (NASDAQ:MDCI), Quidel Corporation (NASDAQ:QDEL), and Gen-Probe Incorporated (NASDAQ:GPRO).
Stock Price Performance: During July 21, 2011 to July 27, 2011, the stock price had dropped $5.48 (-6.2%) from $88.97 to $83.49. The stock price saw one of its best stretches over the last year between July 29, 2010 and August 10, 2010 when shares rose for nine-straight days, rising 7.2% (+$4.76) over that span. It saw one of its worst periods between July 21, 2011 and July 27, 2011 when shares fell for five-straight days, falling 6.2% (-$5.48) over that span. Shares are down 19 cents (-0.2%) year to date.
(Source: Xignite Financials)